GlassScriptPhysician profile
Christopher Alan Woolley
NPI 1659734986
$17,662.22
in general payments reported to CMS, 2019-2025
21 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $9,669 · 2021: $1,087 · 2022: $3,484 · 2023: $1,233 · 2024: $1,259 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,345.01 | 2020-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Medtronic USA, INC. | $4,210.53 | 2020 | |
| Abbott Laboratories | $2,352.54 | 2021-2024 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $1,258.33 | 2021-2023 | Intracept |
| Spr Therapeutics, INC | $357.00 | 2022-2025 | Sprint Pns System |
| Saluda Medical Americas, INC. | $273.92 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $194.60 | 2021-2024 | Intellis Adaptivestim |
| Nalu Medical, INC. | $149.31 | 2021 | |
| Nevro Corp. | $134.56 | 2021-2024 | Senza |
| Merz North America, INC. | $84.68 | 2020 | |
| Abbvie INC. | $71.70 | 2023-2025 | Botox |
| Merz Pharmaceuticals, LLC | $52.47 | 2021 | |
| Globus Medical, INC. | $27.38 | 2025 | Senza |
| Lundbeck LLC | $24.09 | 2020 | |
| Impel Pharmaceuticals INC. | $22.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $20.04 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.48 | 2024 | |
| Allergan, INC. | $16.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.94 | 2021 | |
| Averitas Pharma INC. | $15.76 | 2023 | Qutenza |
| Upsher-Smith Laboratories LLC | $15.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Woolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.